Dear colleagues and friends,

I am very happy to announce that this year ENETS has been improving the society’s processes in many directions. The highlights can be found in this newsletter. Our annual conference, which took place March 8–10 2017, was very well received. Please read more about the feedback from the conference below.

Further, ENETS is developing its educational channel and will be offering webinars covering the Postgraduate Courses in the near future.

Additionally, ENETS has initiated its first Excellence Academy Fellowship meeting. After two years of development and running the expanded grant program successfully, ENETS is delighted to have reached out to a younger audience and to have provided funding for the grant and fellowship recipients who will come together in the fall of this year. The aim is to promote and facilitate inter-group research within ENETS.

In addition, the research/clinical trials area has been expanded and ENETS has provided support for the ASPEN trial, whose aim is to evaluate the optimal management of small (≤2 cm) asymptomatic PanNET.

Due to the great work of the ENETS Advisory Board in 2015 and its follow-up in 2016, the papers for ENETS Standards of Care (SoC) for NEN have been updated and published in Neuroendocrinology in July 2017. Many thanks to the leads, namely Wouter W. de Herder and Marianne Pavel for accomplishing this great task.

The ENETS role within the ERN EURACAN (ERN on adult cancers [solid tumours], https://ec.europa.eu/health/ern/networks_en) is expanding further. Martyn Caplin is heading the subdomain for neuroendocrine neoplasms and working closely together with the EURACAN group. ENETS looks forward to this important collaboration.

ENETS task forces and projects have expanded as well. The ENETS European NET Registry has newly included Poland and plans for France, Italy and Germany are in the pipeline. The number of Centers of Excellence (CoE) has now reached 42. ENETS strongly encourages its continued work with NET Nurse Group and patient advocacy groups.

ENETS has won new staff and as a result restructured in different areas, to better position itself for the growing demands in the future.

Your feedback is important to ENETS. Please contact us at info@enets.org.

Yours,
Massimo Falconi
(ENETS Chairman)
Report on the 14th Annual ENETS Conference

Postgraduate (PG) Course
The Postgraduate Course was visited by more than 640 participants and was positively reviewed by the audience. The aim of the Postgraduate Course was to review advances in neuroendocrine tumors and to serve as complementary addition to the main conference. Martyn Caplin, as lead of the PG Course, gave an overview of the talks covering management of NET. Please view the PG webcasts on MY ENETS any time (see photo above).

Highlights Main Conference
The two-day main conference on 9 and 10 March 2017 was visited by 1,500 participants (see graphic below) from 16 different countries. ENETS has received positive feedback for many of the sessions, especially session 6 'How To Not Do Harm?' and session 10: 'What’s New in the Field?,' which is always popular and meanwhile considered one of the main pillars of the conference. The ENETS Scientific Organizing Committee is thankful for the sound advice and feedback by participants and will adapt the suggestions given for next year’s conference. Please read the summarized reports by Sebastian Krug, Joakim Crona and Wouter Zandee below.

Session 1 (Reported by Joakim Crona)
‘Lessons Learned from Other Cancers’ opened the 14th annual ENETS conference in Barcelona. The first half of this session was devoted to inspirational talks given by speakers from other disciplines. Michal Lotem (see photo above), ‘Immune System and Cancer’, reviewed relevant milestones in cancer immunotherapy. She presented promising predictive biomarkers, including PD-L1 expression, immune cell infiltration, viral etiology as well as mutation load and chromosomal aneuploidy. The second inspirational talk was given by Jan Dumanski, titled "Tumor and Tissue Heterogeneity – What Can We Learn from Breast Cancer". He introduced the audience to the extraordinary complexity of the human body, focusing on postzygotic mosaicism – every cell in our body is genetically distinct from its neighboring cells. It was shown that breast cancer is not a disease of a single cell, but a disease of the whole organ.

Matthew Kulke put these insights into a NET perspective in his talk ‘Immune System and Heterogeneity in Neuroendocrine Tumors’. Immune cell infiltration has clinical relevance in neuroendocrine tumors. Pancreatic neuroendocrine tumors were shown to have higher extratumoral immune cell infiltration compared to small intestinal subtypes. There was no clear association to mutation subtypes.

Finally, in a Presidential Abstract presented by Amit Tirosh (see photo above), ‘Genotype phenotype correlations in VHL related pancreatic NETs’, an algorithm for the treatment of VHL associated pancreatic neuroendocrine tumors was presented. It includes tumor size as well as VHL genotyping.

Session 2A and 3A (Reported by Sebastian Krug)
Session 2A on Thursday, 9 March covered ‘Tumorigenic Mechanisms of NET’. Leandro Castellano from the UK started to present data about a global miRNome approach to identifying differentially regulated miRNAs in primary and metastases of the small bowel NET. The group aimed to characterize miRNAs as biomarkers to stratify patients and guide treatment decisions. Afterwards, Aldo Scarpa (Italy) explained his previously published Nature paper regarding: ‘Whole-genome landscape of pancreatic neuroendocrine tumours’. This hallmark paper included whole-genome sequencing in more than 100 well-differentiated PanNET to reveal e.g. different mutational signatures in this entity. Since molecular understandings in NET are still limited, this study intended to present the complex tumor biology in PanNET.
The link to translational approaches and clinical implications remained open and has to be clarified in the future. The session ended with presentations of Leo Hofland and Jonathan Benhamou (see photo above).

Leo Hofland introduced a therapeutic approach to in-vitro to reconstitute SSTR2 expression in Bon1 and QGP1 cells via treatment with epigenetic regulators such as valproic acid and 5-aza. The epidermal-induced upregulation of SSTR2 might hold promising treatment strategies for SSA or PRRT.

Jonathan Benhamou assessed three main signaling pathways in Merkel cell carcinoma and correlated his results with prognosis and viral status.

During Session 3A, there was a highly interesting debate about the role of surgery in patients with aggressive G3 NEN. Before, Aurel Perren underlined the importance to distinguish between NET G3 and NEC G3. Both entities tremendously vary in terms of clinical course and tumor biology, and thus should be treated differently. Thereafter, Halfdan Sørbye gave his PRO arguments for surgery, while Ulrich Knigge counteracted. The discussants agreed to offer surgery for patients with localized or regional NEN G3 regardless of origin, however, data for esophageal G3 NEN concluded to use chemoradiation upfront. The role of surgery in patients with metastatic NEC G3 is ambiguous. Currently, it is not recommended, but selected patients may however benefit from this approach.

Session 9B (Reported by Wouter Zandee)

Session 9B clearly described all the challenges and controversies in the treatment of neuroendocrine tumors, but answers were not always available. Gregory Kaltsas kicked off the session by describing the benign behavior of appendecial NET. Good quality data is lacking to judge the indication for hemicolecetomy as even lymphnode metastases do not seem to influence survival. For pancreatic NET, minimal invasive surgery can be indicated. However in small intestinal NET, open surgery is still advised because of the node and peritoneal metastases. Resection of peritoneal metastases might increase survival as described by Léonor Benhaim in her Presidential Abstract. The largest controversy remains the sequencing of therapy, and this question remained unanswered.

Life Achievement Award 2017

Kjell Öberg was the recipient of the Life Achievement Award 2017. ENETS is immensely thankful for his exceptional contribution to the Society of which he was also the founder and the first chairman in 2004 (see photo above). In her dedication to Kjell Öberg, Eva Tiensuu Janson stressed that Kjell Öberg understood early that it is important to have a multi-disciplinary team to treat patients. He established the first endocrine department in 1991, which is dedicated to diagnosis and treatment of NET at the Uppsala University. Kjell Öberg’s important work in research led to the usage of Alpha Interferon as a treatment for neuroendocrine tumors and he published an important paper in 1983 titled ‘Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid Syndrome’, where it was proven that Alpha Interferon can actually help patients with small intestines with neuroendocrine tumors. Many of his ground breaking research milestones were portrayed in Eva’s dedication, which was followed by Kjell Öberg’s talk. They can be viewed on the MY ENETS www.enets.org/my_enets.html.

A Joint Symposium of INCA and ENETS – 1st Patient Symposium

The INCA/ENETS Symposium (see photo above) was the first of its kind and not only offered insight but also initiated discussions about patients coping with NET, however, targeting at Unmet Medical Needs in NET. The introduction was held by Massimo Falconi, who together with Ron Hollander (INCA president) and Teodora Kolarova (INCA Executive Director) laid out the importance of the cooperation between patients and doctors. Massimo Falconi stressed that patients are the true protagonists and that he is very happy this special event can take place during scientific sessions. Ron Hollander followed-up by thanking
Grant Awards Recipients 2017

ENETS CoE Young Investigator Grant Recipient 2017
Alexa Childs, GBR (See photo above)

ENETS Excellence Academy Fellowship Grant Recipients 2017
Elettra Merola, ITA (See photo above)
Mauro Cives, ITA (See photo above)

ENETS Translational Medicine Fellowship 2017
Gianfranca Coma, ITA (See photo above)

ENETS CoE Training Fellowship Grant Recipients 2017
Om Jitendra Lakhani, IND
Anna Caterina Milanetto, ITA
Manila Rubino, ITA

ENETS Håkan Ahlman Award Recipient 2017
Rajesh Thakker, GBR

Bertram Wiedenmann for his immense effort in initiating this dialogue. The symposium ends with a panel discussion between physicians, nurses and patient advocacy. Please view this significant symposium on MY ENETS www.enets.org/my_enets.html.

Nurse Workshop on Thursday, 9 March 2017 (Reported by Jenny Falkerby) (see photo above on the left page)
'This year, we tried out a Nurse Workshop alongside the ‘Meet the Professor’ sessions. It turned out to be a success. We had two parallel topics to be discussed along with the nurses to the theme 'Reality in Practice – Gastro-Intestinal Symptoms and Quality of Life in Patients with NET.' The discussions were lively and fruitful and we could have prolonged the session for another hour'.

Nurse Symposium on Friday, 10 March 2017 (Reported by Jenny Falkerby)
'Martyn Caplin and Philippa Davies introduced the speakers and Michael Tadman started with the survey performed in the UK investigating the use of long-acting Somatostatin Analogues in NET.
Based on the results, it would be of interest to conduct that study in more European countries.
Tara Whyard from UK had an interesting speech about small bowel bacterial overgrowth that is a challenging problem among patients with NET. It is a condition where we need to receive the knowledge about, both how we diagnose and also treat this. The condition may be limiting and have a major impact on the patient’s quality of life.’
Oral Abstract and Poster Award Recipients 2017

Sebastien Gaujoux  
FRA  
1st Place for Best Oral Clinical Abstract Presentation

Wouter Zandee  
NED  
2nd Place for Best Oral Clinical Abstract Presentation

Julien Bollard  
FRA  
1st Place for Best Oral Basic Science Abstract Presentation

Ilaria Marinoni  
SUI  
2nd Place for Best Oral Basic Science Abstract Presentation

Sjoerd Nell  
NED  
1st Place for Poster in the Clinical Category

Daan Smit Duijzentkunst  
NED  
2nd Place for Poster in the Clinical Category

Leonidas Apostolidis  
GER  
3rd Place for Poster in the Clinical Category

Angela Lamarca  
GBR  
1st Place for Poster in the Basic Science Category

Alberto Carmona-Bayonas  
ESP  
2nd Place for Poster in the Basic Science Category

Gema Marin Zafra  
ESP  
2nd Place for Poster in the Basic Science Category

Thank you to the 14th Annual ENETS Conference Scientific Organizing Committee 2017

Martyn Caplin  
GRB

Rocio Garcia-Carbonero  
ESP

Wouter W. de Herder  
NED

Massimo Falconi  
ITA

Reza Kianmanesh  
FRA

Kjell Öber  
SWE

Dermot O'Toole  
IRL

Marianne Pavel  
GER

Aurel Perren  
SUI

Bertram Wiedenmann  
GER

Thank you to the Annual Conference Barcelona 2017 ENETS Team

Malgorzata Szott-Emus  
(Project Manager for ENETS Annual Conferences)

Vanessa Tatum  
(Program Development, Public Relations, ENETS Office Coordinator)

Simon Hirschmann  
(Technical Manager)

Christoph Hubener  
(Logistics)

Ulrike Knell  
(Event Manager, ENETS Office Project Assistant)

Marcus Lelle  
(Antwort Internet, IT-Support, Website Programmer)

Lenz Leberkern  
(Graphic Designer, Merchandising)

Oliver Fischer  
(Photographer)

Ramish Dussoye  
and his team (Du.St., Hostesses' Service)

ENETS Travel Grant Recipients 2017

Julien Bollard  
FRA

David L. Chan  
CAN

Luohai Chen  
CHN

Jules Derks  
NED

Fatima Arooj  
PAK

Angela Lamarca  
GBR

Faidon Laikarakos  
GBR

Yang Lv  
CHN

Maria Rinzivillo  
ITA

Concetta Sciammarella  
ITA

Amit Tirosh  
USA

Rachel van Leeuwaarde  
NED

Rudolf Werner  
GER

ENETS Standards of Care (SoC) Update 2017

The paper for the updated ENETS Standard of Care (SoC) has been published in Neuroendocrinology in July 2017.

Introduction by Wouter W. de Herder and Marianne Pavel (Source: Neuroendocrinology (DOI: 10.1159/000457957))
While recently updated and published Consensus Guidelines for the management of digestive neuroendocrine tumors (Neuroendocrinology 2016;103:117ff) provide guidance for appropriate therapy selection, standards of care needed to be addressed for recently introduced novel therapies and updated for established standard therapies. The same group of experts who developed the recent ENETS Consensus Guidelines update for the management of patients with digestive neuroendocrine tumors convened at a consensus meeting held in Antibes on November 5–6 in 2015 to update technical and practical details necessary for implementing consensus guidelines.

The consensus sessions covered the following topics:
- Pathology – Diagnosis and Prognostic Stratification
- Biochemical Markers
- Radiological, Nuclear Medicine & Hybrid Imaging
- Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours
- Pre- and Perioperative Therapy
- Systemic Therapy: Biotherapy, Novel Targeted Agents, Chemotherapy
- Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues
- Follow-Up and Documentation in Patients with Neuroendocrine Tumours

To access the SoC papers, please go online to Karger or as an ENETS member directly to MY ENETS. www.enets.org/my_enets.html

Congratulations to the new ENETS Centers of Excellence (CoE)

Prof. Dermot O’Toole
NET Centre SVUH (National Centre)
Neuroendocrine Tumour Centre
St Vincent’s University Hospital
Elm Park
D4 Dublin
Ireland

Prof. Michael Scheurlen
NET Zentrum Würzburg
Interdisziplinäres Zentrum für Neuroendokrine Tumoren Würzburg
Oberdurrbacher Str. 6–8
97070 Würzburg
Germany

Prof. Marc Peeters
Dr. Willem Lybaert
NETwerk Antwerpen
c/o UZ Antwerpen
Department of Oncology
Wilrijkstraat 10
2650 Egedem
Belgium

Prof. Patricia Niccoli
Institut Paoli-Calmettes
Bd St Marguerite BP156
Marseille cedex 09
France

Prof. Gregory Kaltsas
EKPA-LAIKO CENTER
Laiko General Hospital of Athens
Agiou Thoma 17
11527 Goudi, Athens
Greece

MY ENETS

Please visit the member’s area MY ENETS. ENETS is looking forward to hearing from its members on how it has helped them find the information they need to learn more about ENETS projects.

Please stay tuned for more updates in MY ENETS, which will soon offer E-learning directly within two clicks, allowing one to receive CME credits, managing your profile member account and accessing the 14th Annual ENETS Conference 2017 webcasts. Please send any suggestions for ‘MY ENETS’ to info@enets.org.
ENETS Annual Conference 2017 Impressions
Save the Date!

The next call for ENETS abstracts, grants and awards within the framework of the 15th Annual ENETS Conference, which is taking place 7–9 March 2018, will begin soon.